News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Baxter International, Inc. (BAX) Presents Data At EAHAD From Long-Term Outcomes Registry Reinforcing Prophylaxis Treatment Experience With ADVATE


2/27/2014 10:00:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRUSSELS--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today presented clinical data on Baxter’s leading recombinant factor VIII treatment, including interim data from the first year of observation from the AHEAD (ADVATE HaEmophilia A Database) study, a four-year outcomes registry of hemophilia A patients treated with ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method]. These data were presented during the European Association for Haemophilia and Allied Disorders (EAHAD) meeting in Brussels, Belgium.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES